share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  10/15 14:04

Moomoo AI 已提取核心訊息

Conduit Pharmaceuticals Inc. has reported a material definitive agreement involving its wholly-owned subsidiary, Conduit Pharmaceuticals Limited, and the issuance of a Convertible Promissory Note to Vrezh Isayan and Sharon Lee Isayan. The note, originally due on September 20, 2024, with a principal amount of $800,000 and an interest rate of 20% per annum, was amendable to extend the maturity date to October 20, 2024. The amendment, effective as of September 20, 2024, also allowed for the issuance of $80,000 worth of the company's common stock and 2,000,000 shares to cover accrued interest and principal. The company has the discretion to further extend the repayment date to November 19 or December 19, 2024. On October 11, 2024, Conduit Pharmaceuticals Inc. issued 2,781,250 shares of common stock in fulfillment of the obligations under the amendment. The details of the Convertible Note and the Loan Extension Amendment were filed with the SEC and are included as exhibits in the company's current report.
Conduit Pharmaceuticals Inc. has reported a material definitive agreement involving its wholly-owned subsidiary, Conduit Pharmaceuticals Limited, and the issuance of a Convertible Promissory Note to Vrezh Isayan and Sharon Lee Isayan. The note, originally due on September 20, 2024, with a principal amount of $800,000 and an interest rate of 20% per annum, was amendable to extend the maturity date to October 20, 2024. The amendment, effective as of September 20, 2024, also allowed for the issuance of $80,000 worth of the company's common stock and 2,000,000 shares to cover accrued interest and principal. The company has the discretion to further extend the repayment date to November 19 or December 19, 2024. On October 11, 2024, Conduit Pharmaceuticals Inc. issued 2,781,250 shares of common stock in fulfillment of the obligations under the amendment. The details of the Convertible Note and the Loan Extension Amendment were filed with the SEC and are included as exhibits in the company's current report.
Conduit Pharmaceuticals Inc.已報告一項涉及其全資子公司Conduit Pharmaceuticals Limited的重大確切協議，涉及向Vrezh Isayan和Sharon Lee Isayan發行可轉讓本票。原定於2024年9月20日到期的票據，本金爲80萬美元，年利率爲20%，已經更改以延長到2024年10月20日。有效日期爲2024年9月20日的修正措施還允許發行價值8萬美元的公司普通股和200萬股以支付應計利息和本金。公司有權將還款日期進一步延長至2024年11月19日或12月19日。2024年10月11日，Conduit Pharmaceuticals Inc.發行了2781250股普通股，以履行修改協議下的義務。可轉讓票據和貸款延期修正案的詳細信息已向美國證券交易委員會提交，並作爲公司當前報告的附件。
Conduit Pharmaceuticals Inc.已報告一項涉及其全資子公司Conduit Pharmaceuticals Limited的重大確切協議，涉及向Vrezh Isayan和Sharon Lee Isayan發行可轉讓本票。原定於2024年9月20日到期的票據，本金爲80萬美元，年利率爲20%，已經更改以延長到2024年10月20日。有效日期爲2024年9月20日的修正措施還允許發行價值8萬美元的公司普通股和200萬股以支付應計利息和本金。公司有權將還款日期進一步延長至2024年11月19日或12月19日。2024年10月11日，Conduit Pharmaceuticals Inc.發行了2781250股普通股，以履行修改協議下的義務。可轉讓票據和貸款延期修正案的詳細信息已向美國證券交易委員會提交，並作爲公司當前報告的附件。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間